Market Cap 2.03B
Revenue (ttm) 51.95M
Net Income (ttm) -265.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -511.92%
Debt to Equity Ratio 0.12
Volume 3,703,200
Avg Vol 3,699,468
Day's Range N/A - N/A
Shares Out 218.96M
Stochastic %K 20%
Beta 0.93
Analysts Strong Sell
Price Target $25.83

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 357 4000
Address:
15 Crosby Drive, Bedford, United States
IchthysTrades
IchthysTrades May. 13 at 10:51 AM
$OCUL Transcript from last evening’s investor chat with BOA. https://seekingalpha.com/article/4903506-ocular-therapeutix-inc-ocul-presents-at-bank-of-america-global-healthcare-conference-2026
0 · Reply
WarrenDouglasTrader
WarrenDouglasTrader May. 13 at 4:41 AM
$OCUL Cant recall hearing a more confident CEO. File the damn NDA already! Wtf
0 · Reply
SmokenTuna
SmokenTuna May. 12 at 11:14 PM
$OCUL we may go it alone if we don’t get our price. Pravin was clear on the ramp up..
4 · Reply
john1chef
john1chef May. 12 at 11:13 PM
$OCUL when I hear pravin talk
0 · Reply
Appulen
Appulen May. 12 at 8:19 PM
$OCUL Dugel has a truckload of incentive shares waiting for him if the price hits 30. This is the magic number to look out for. The shareholder structure of Ocul is made up entirely of investment institutions. They don't know how to and they don't want to manage a pharmaceutical company. Once the right buyer with the right price comes along, these shareholders will want to cash and collect their return on investment. This is the nature of the small single product biopharma industry. Investigate, create, liquidate. Repeat.
3 · Reply
esu89
esu89 May. 12 at 5:09 PM
$OCUL PLEASE KEEP SHORTING!!! I’d like to see the shares short up to at least 30 million in the next month. The more the merrier as far as I’m concerned.
1 · Reply
phonesearch
phonesearch May. 12 at 3:23 PM
$OCUL hanging in here.....you don't think they are positioning themselves for a buyout at a higher offer? Made the mistake of selling the last time I thought this on another one of my positions, and what do you know? Huge buyout that I didn't get to partake in because I got too impatient...not doing that again.
1 · Reply
Tmoney85285
Tmoney85285 May. 12 at 2:57 PM
$OCUL live look at jjarnold driving his sports car with fellow bulls in the middle of scranton LMAO
0 · Reply
kundalini56
kundalini56 May. 12 at 1:41 PM
$OCUL GM all. We are continuing to average down here. Believe that patience will be rewarded. The upcoming Retina conference in May and the June Investors meeting should be great catalysts to boost SP.
0 · Reply
MaxKlim
MaxKlim May. 12 at 9:32 AM
0 · Reply
Latest News on OCUL
Ocular Therapeutix Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 7 days ago

Ocular Therapeutix Earnings Call Transcript: Q1 2026


Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

2026-05-05T11:59:32.000Z - 7 days ago

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)


Ocular Therapeutix enrolls first patient in Axpali trial

2026-04-29T13:00:19.000Z - 13 days ago

Ocular Therapeutix enrolls first patient in Axpali trial


Ocular Therapeutix Transcript: HCW @ Home

Apr 27, 2026, 2:30 PM EDT - 15 days ago

Ocular Therapeutix Transcript: HCW @ Home


Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Apr 22, 2026, 7:00 AM EDT - 21 days ago

Ocular Therapeutix™ to Host Investor Day on June 17, 2026


Ocular Therapeutix reports additional Axpaxli trial data

2026-04-13T11:22:45.000Z - 4 weeks ago

Ocular Therapeutix reports additional Axpaxli trial data


Ocular Therapeutix price target raised to $27 from $24 at BofA

2026-03-03T11:45:13.000Z - 2 months ago

Ocular Therapeutix price target raised to $27 from $24 at BofA


Ocular Therapeutix Transcript: Study update

Mar 2, 2026, 7:30 AM EST - 2 months ago

Ocular Therapeutix Transcript: Study update


Ocular Therapeutix Transcript: Study result

Feb 17, 2026, 8:00 AM EST - 3 months ago

Ocular Therapeutix Transcript: Study result


Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)

2026-02-05T12:05:13.000Z - 3 months ago

Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)


Ocular Therapeutix rises 11.7%

2026-01-15T15:06:31.000Z - 4 months ago

Ocular Therapeutix rises 11.7%


Ocular Therapeutix price target raised to $21 from $18 at BofA

2025-12-12T13:36:48.000Z - 5 months ago

Ocular Therapeutix price target raised to $21 from $18 at BofA


Ocular Therapeutix Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 6 months ago

Ocular Therapeutix Earnings Call Transcript: Q3 2025


Ocular Therapeutix Transcript: Investor Day 2025

Sep 30, 2025, 2:00 PM EDT - 8 months ago

Ocular Therapeutix Transcript: Investor Day 2025


Ocular Therapeutix Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Ocular Therapeutix Earnings Call Transcript: Q2 2025


Ocular Therapeutix Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q4 2024


Ocular Therapeutix Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q3 2024


Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day

Oct 2, 2024, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day


Ocular Therapeutix Earnings Call Transcript: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q2 2024


Ocular Therapeutix™ Reports Second Quarter 2024 Results

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results


Ocular Therapeutix Transcript: Investor Day 2024

Jun 13, 2024, 2:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: Investor Day 2024


Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 5, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024


Ocular Therapeutix™ Reports First Quarter 2024 Results

May 7, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix™ Reports First Quarter 2024 Results


IchthysTrades
IchthysTrades May. 13 at 10:51 AM
$OCUL Transcript from last evening’s investor chat with BOA. https://seekingalpha.com/article/4903506-ocular-therapeutix-inc-ocul-presents-at-bank-of-america-global-healthcare-conference-2026
0 · Reply
WarrenDouglasTrader
WarrenDouglasTrader May. 13 at 4:41 AM
$OCUL Cant recall hearing a more confident CEO. File the damn NDA already! Wtf
0 · Reply
SmokenTuna
SmokenTuna May. 12 at 11:14 PM
$OCUL we may go it alone if we don’t get our price. Pravin was clear on the ramp up..
4 · Reply
john1chef
john1chef May. 12 at 11:13 PM
$OCUL when I hear pravin talk
0 · Reply
Appulen
Appulen May. 12 at 8:19 PM
$OCUL Dugel has a truckload of incentive shares waiting for him if the price hits 30. This is the magic number to look out for. The shareholder structure of Ocul is made up entirely of investment institutions. They don't know how to and they don't want to manage a pharmaceutical company. Once the right buyer with the right price comes along, these shareholders will want to cash and collect their return on investment. This is the nature of the small single product biopharma industry. Investigate, create, liquidate. Repeat.
3 · Reply
esu89
esu89 May. 12 at 5:09 PM
$OCUL PLEASE KEEP SHORTING!!! I’d like to see the shares short up to at least 30 million in the next month. The more the merrier as far as I’m concerned.
1 · Reply
phonesearch
phonesearch May. 12 at 3:23 PM
$OCUL hanging in here.....you don't think they are positioning themselves for a buyout at a higher offer? Made the mistake of selling the last time I thought this on another one of my positions, and what do you know? Huge buyout that I didn't get to partake in because I got too impatient...not doing that again.
1 · Reply
Tmoney85285
Tmoney85285 May. 12 at 2:57 PM
$OCUL live look at jjarnold driving his sports car with fellow bulls in the middle of scranton LMAO
0 · Reply
kundalini56
kundalini56 May. 12 at 1:41 PM
$OCUL GM all. We are continuing to average down here. Believe that patience will be rewarded. The upcoming Retina conference in May and the June Investors meeting should be great catalysts to boost SP.
0 · Reply
MaxKlim
MaxKlim May. 12 at 9:32 AM
0 · Reply
MaxKlim
MaxKlim May. 12 at 9:28 AM
0 · Reply
Nibbler
Nibbler May. 12 at 1:32 AM
$OCUL I hope this ticker blows up so i can go to vegas.
0 · Reply
rstrau
rstrau May. 12 at 12:50 AM
$OCUL, short interest on 4/30 came in about a quarter of a million shares higher than on 4/15. The days to cover based on average shares traded in the period is the highest it has been in a year. Since the 1/30 numbers, which were the last numbers prior to topline data being released, and the 4/30 numbers, short interest has increased from 11.5 million shares to 24.7 million shares and days to cover increased from 2.2 days to 8.5 days, while price has increased from 9.14 to 9.28 and institutions have added.
1 · Reply
kundalini56
kundalini56 May. 12 at 12:21 AM
$OCUL Some here are longtime OCUL holder (from the 4 onwards). We are in this from this from Jan -avg 10.2- but lot invested here. Options prices here look good. Question- Is averaging down a good option at this point with OCUL? Thank you.
1 · Reply
davetoma
davetoma May. 11 at 11:16 PM
$OCUL Tmoney been saying ocul gonna be below 9 for 2 months now! Just repeating the same thing over and over and over doesn't make you a soothsayer lol maybe it will happen maybe it won't but I'll make some predictions too like Tmoney.... 1...there will be a cloud in the sky this week 2...everyone on here will breathe in oxygen today 3...the market will go up or down Lol let's see which of these comes true!
4 · Reply
Tmoney85285
Tmoney85285 May. 11 at 5:09 PM
$OCUL another banner day for ol OCUL! reading some these comments is both laughable and sad. see you all under 9!
0 · Reply
Fairvalue10
Fairvalue10 May. 11 at 9:45 AM
$OCUL Despite Makary's departure, Ocular's SPA, a binding agreement with the FDA on SOL-1's trial design, remains fully enforceable regardless of who leads the agency, making it the strongest regulatory protection available. Given the current uncertainty around FDA leadership, Ocular has every incentive to file its NDA as quickly as possible to lock in the review process under the existing single-trial policy before any potential shift in regulatory direction.
2 · Reply
chiefresident
chiefresident May. 10 at 3:29 PM
$OCUL if Makary is fired. Do u think FDA will mandate two studies? This a tricky situation if he is fired.
4 · Reply
fsu45
fsu45 May. 9 at 12:45 PM
$OCUL Did anyone notice that NASDAQ institutional investors went from just a hair under 89% to 94.21%??? Did major institutions just purchase over 5% more of OCUL? This has to be huge. Anyone's thoughts?
5 · Reply
Quantumup
Quantumup May. 8 at 7:24 PM
BofA reiterated Top Pick $OCUL Buy; $27 in its SMID cap investor's guide to Health Care (including top stock ideas) $EYPT REGN FDMT RHHBY KOD $SRZN Here's what BofA said in its note: https://x.com/Quantumup1/status/2052831264231526811?s=20
0 · Reply
Wisconsin1960
Wisconsin1960 May. 8 at 1:31 PM
$OCUL I believe that insurance companies will be an important part of this conversation. They will see Ocul’s product as a lower cost option. In the first year a patient needs at least 6 Eylea treatments compared to 2 using Ocul’s proposed product.
2 · Reply
TBillyhatesmoney
TBillyhatesmoney May. 8 at 1:00 PM
$OCUL Does the label for HD state that you have to go through a year of 2 mg before transitioning if your niave? no previous treatment
1 · Reply